AR074771A1 - Derivados de imidazol biciclicos sustituidos como moduladores de gamma secretasa - Google Patents
Derivados de imidazol biciclicos sustituidos como moduladores de gamma secretasaInfo
- Publication number
- AR074771A1 AR074771A1 ARP090104939A ARP090104939A AR074771A1 AR 074771 A1 AR074771 A1 AR 074771A1 AR P090104939 A ARP090104939 A AR P090104939A AR P090104939 A ARP090104939 A AR P090104939A AR 074771 A1 AR074771 A1 AR 074771A1
- Authority
- AR
- Argentina
- Prior art keywords
- halo
- alkyl
- alkyloxy
- substituents
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
Abstract
La solicitud también se refiere a composiciones farmacéuticas que comprenden dichos nuevos compuestos como ingredientes activos, así como al uso de dichos compuestos como medicamentos. Reivindicación 1: Un compuesto de fórmula (1) o una forma estereoisomérica de dicho compuesto, en donde R0 es hidrógeno, halo o alquilo C1-4; R1 es hidrógeno, alquilo C1-4 o halo; X es CR7 o N; en donde R7 es hidrógeno o halo; A1 es CR2 o N; A2 es CR o N; A3 y A4, cada uno independientemente, son CH o N; con la condición de que no más de dos de A1, A2, A3 y A4 sean N; R2 es hidrógeno, halo o alquiloxi C1-4; R8 es hidrógeno o halo; R3 es hidrógeno; alquilo C1-6 opcionalmente sustituido con uno o varios sustituyentes, cada uno seleccionado independientemente del grupo que consiste en hidroxilo, halo, morfolinilo, piperidinilo, pirrolidinilo, tetrahidropiranilo, Ar, alquiloxi C1-6, cicloalquiloxi C3-7 y cicloalquilo C3-7; carboxilo; alquenilo C2-4; NR5R6-carbonilo; cicloalquilo C3-7; Ar; tetrahidropiranilo; alquilcarbonilo C1-6; alquiloxicarbonilo C1-6; o Ar-O-CH2-; en donde cada Ar es independientemente fenilo opcionalmente sustituido con uno o vados sustituyentes, cada uno seleccionado independientemente del grupo que consiste en halo, alquiloxi C1-4, ciano, NR5R6, morfolinilo, alquilo C1-4 y alquilo C1-4 sustituido con uno o varios sustituyentes, cada uno seleccionado independientemente del grupo que consiste en halo, alquiloxi C1-4 y NR5R6; bencimidazolilo opcionalmente sustituido con uno o varios sustituyentes, cada uno independientemente seleccionado de alquilo C1-4; o piridinilo opcionalmente sustituido con uno o varios sustituyentes, cada uno seleccionado independientemente del grupo que consiste en halo, alquiloxi C1-4, ciano, alquilo C1-4 y alquilo C1-4 sustituido con uno o varios sustituyentes, cada uno independientemente seleccionado de halo; cada R5 es independientemente hidrógeno, alquilo C1-4, alquilcarbonilo C1-6 o alquiloxi C1-4(CH2CH2O)n-CH2-carbonilo; n es un número entero seleccionado de 1, 2, 3, 4, 5 o 6; cada R6 es independientemente hidrógeno o alquilo C1-4; R4 es hidrógeno; ciano; halo; fenilo opcionalmente sustituido con uno o varios sustituyentes, cada uno seleccionado independientemente del grupo que consiste en halo y fenilo; fenilcarbonilo opcionalmente sustituido con uno o varios sustituyentes, cada uno independientemente seleccionado de halo; alquiloxi C1-4; aIquilo C1-6 opcionalmente sustituido con uno o varios sustituyentes, cada uno seleccionado independientemente del grupo que consiste en halo, NR5R6, alquiloxi C1-4, hidroxilo y formilamino; Y1 es CH o N; Y2 es CR9 o N; Y3 es CH o N; con la condición de que sólo uno de Y1, Y2 y Y3 represente N; R9 es hidrógeno; halo; alquiloxi C1-4; ciano; cicloalquilo C3-7; tetrahidropiranilo; alquenilo C2-4; fenilo opcionalmente sustituido con uno o varios sustituyentes, cada uno independientemente seleccionado de alquiloxi C1-4; o aIquilo C1-4 opcionalmente sustituido con uno o vados sustituyentes, cada uno seleccionado independientemente del grupo que consiste en halo y alquiloxi C1-4; o una sal de adición farmacéuticamente aceptable o un solvato de dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08172202 | 2008-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074771A1 true AR074771A1 (es) | 2011-02-09 |
Family
ID=40451180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104939A AR074771A1 (es) | 2008-12-18 | 2009-12-17 | Derivados de imidazol biciclicos sustituidos como moduladores de gamma secretasa |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8546440B2 (es) |
| EP (1) | EP2379552B1 (es) |
| JP (2) | JP2012512831A (es) |
| KR (1) | KR20110102455A (es) |
| CN (1) | CN102256974B (es) |
| AP (1) | AP2011005692A0 (es) |
| AR (1) | AR074771A1 (es) |
| AU (1) | AU2009327103B2 (es) |
| BR (1) | BRPI0922664A2 (es) |
| CA (1) | CA2742914A1 (es) |
| EA (1) | EA018625B1 (es) |
| ES (1) | ES2460642T3 (es) |
| IL (1) | IL213563A (es) |
| MX (1) | MX2011006543A (es) |
| NZ (1) | NZ594036A (es) |
| PA (1) | PA8854101A1 (es) |
| SG (1) | SG172213A1 (es) |
| TW (1) | TWI438203B (es) |
| UA (1) | UA104151C2 (es) |
| WO (1) | WO2010070008A1 (es) |
| ZA (1) | ZA201104504B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| BRPI0921317A2 (pt) | 2008-11-06 | 2017-06-06 | Astrazeneca Ab | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| AP2011005779A0 (en) | 2009-02-06 | 2011-08-31 | Ortho Mcneil Janssen Pharm | Novel susbstituted bicyclic heterocyclic compoundsas gamma secretase modulators. |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| NZ596843A (en) | 2009-05-07 | 2012-12-21 | Janssen Pharmaceuticals Inc | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| EP2454239B1 (en) | 2009-07-15 | 2014-08-13 | Janssen Pharmaceuticals Inc. | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| BR112012017310A2 (pt) | 2010-01-15 | 2016-04-19 | Janssen Pharmaceuticals Inc | derivados de triazol substituídos como moduladores de gama secretase |
| WO2012013713A2 (en) | 2010-07-28 | 2012-02-02 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-b]pyridazines |
| KR20140047032A (ko) | 2011-03-24 | 2014-04-21 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조정제로서의 신규 치환 트리아졸릴 피페라진 및 트리아졸릴 피페리딘 유도체 |
| WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| ES2545135T3 (es) | 2011-04-06 | 2015-09-08 | Bayer Pharma Aktiengesellschaft | Imidazopiridinas sustituidas y compuestos intermedios de las mismas |
| HUE026323T2 (en) | 2011-04-07 | 2016-05-30 | Bayer Ip Gmbh | Imidazopyridazines as AKT kinase inhibitors |
| IN2014MN00258A (es) | 2011-07-15 | 2015-09-25 | Janssen Pharmaceuticals Inc | |
| AU2012325909B2 (en) | 2011-10-20 | 2016-06-09 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| EP2768833A4 (en) * | 2011-10-20 | 2015-04-15 | Sirtris Pharmaceuticals Inc | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS MODULATORS OF SIRTUINS |
| WO2013064445A1 (en) * | 2011-11-01 | 2013-05-10 | F. Hoffmann-La Roche Ag | Imidazopyridazine compounds |
| CN104159891B (zh) | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
| AU2013261023B2 (en) | 2012-05-16 | 2016-11-24 | Cellzome Limited | Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease |
| FR2993564B1 (fr) | 2012-07-20 | 2014-08-22 | Metabrain Res | Derives d'imidazopyridine utiles dans le traitement du diabete |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| CA2889249C (en) | 2012-12-20 | 2021-02-16 | Francois Paul Bischoff | Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators |
| EP2945944B1 (en) | 2013-01-17 | 2016-11-09 | Janssen Pharmaceutica, N.V. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| BR112015030678A8 (pt) * | 2013-06-12 | 2020-01-07 | Janssen Pharmaceutica Nv | derivados 4-amino-6-fenil-5,6-di-hidroimidazo [1,5-a] pirazina como inibidores de beta-secretase (bace), composição farmacêutica, processo para preparação da mesma, e usos na fabricação de medicamentos |
| EA032662B1 (ru) * | 2013-06-12 | 2019-06-28 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 4-АМИНО-6-ФЕНИЛ-5,6-ДИГИДРОИМИДАЗО[1,5-а]ПИРАЗИН-3(2H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| ES2768823T3 (es) | 2014-12-18 | 2020-06-23 | Janssen Pharmaceutica Nv | Derivados de 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2H-pirrol-5-amina útiles como inhibidores de beta-secretasa |
| CA3202893A1 (en) * | 2014-12-23 | 2016-06-30 | Gilead Science, Inc. | Processes for preparing ask1 inhibitors |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| CN107743486B (zh) * | 2015-03-12 | 2021-04-09 | Fmc公司 | 杂环取代的二环唑杀有害生物剂 |
| ES2955596T3 (es) * | 2018-10-05 | 2023-12-04 | Corteva Agriscience Llc | Proceso e intermedios para la preparación de determinadas sulfonamidas nematicidas |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5702201A (en) | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| DE10238002A1 (de) | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | Benzimidazolderivate |
| AU2004247013B2 (en) | 2003-05-14 | 2010-07-08 | Neurogenetic Pharmaceuticals, Inc. | Compounds and uses thereof in modulating amyloid beta |
| DE602005023965D1 (de) | 2004-03-08 | 2010-11-18 | Prosidion Ltd | Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase |
| KR101128065B1 (ko) | 2004-05-26 | 2012-04-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
| AU2005297966B2 (en) | 2004-10-26 | 2010-12-23 | Eisai R & D Management Co., Ltd. | Amorphous object of cinnamide compound |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2007043786A1 (en) * | 2005-10-10 | 2007-04-19 | Seiyang Yang | Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same |
| EP1937767B1 (en) | 2005-10-11 | 2013-05-22 | Chemtura Corporation | Diaromatic amines |
| US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| US7893058B2 (en) * | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| US7951818B2 (en) * | 2006-12-01 | 2011-05-31 | Galapagos Nv | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2008082490A2 (en) * | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| AU2008214372A1 (en) | 2007-02-08 | 2008-08-14 | Merck Sharp & Dohme Corp. | Therapeutic agents |
| RU2009144998A (ru) * | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
| BRPI0811993A2 (pt) | 2007-05-11 | 2014-11-18 | Hoffmann La Roche | " hetarilanilinas como moduladores para beta-amiloide ". |
| EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES |
| WO2009005729A1 (en) | 2007-06-29 | 2009-01-08 | Schering Corporation | Gamma secretase modulators |
| US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| CA2698341A1 (en) | 2007-09-06 | 2009-03-12 | Schering Corporation | Gamma secretase modulators |
| JP2011502244A (ja) | 2007-10-19 | 2011-01-20 | エラック エイエス | Ｅｄｔａ耐性ｓ１００ａ１２複合体（ｅｒａｃ） |
| KR20100094554A (ko) | 2007-12-06 | 2010-08-26 | 쉐링 코포레이션 | 감마 세크레타제 조절인자 |
| WO2009076352A1 (en) | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
| CA2713716A1 (en) | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| US20120129846A1 (en) * | 2008-11-06 | 2012-05-24 | Zhaoning Zhu | Gamma secretase modulators |
| CA2744152A1 (en) | 2008-12-03 | 2010-06-10 | Via Pharmaceuticals, Inc. | Inhibitors of diacylglycerol acyltransferase |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| AP2011005779A0 (en) | 2009-02-06 | 2011-08-31 | Ortho Mcneil Janssen Pharm | Novel susbstituted bicyclic heterocyclic compoundsas gamma secretase modulators. |
| TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
| JP2012051806A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| EP2424866A1 (en) | 2009-04-27 | 2012-03-07 | High Point Pharmaceuticals, LLC | Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as -secretase inhibitors |
| NZ596843A (en) | 2009-05-07 | 2012-12-21 | Janssen Pharmaceuticals Inc | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators |
| JP2010274429A (ja) | 2009-05-26 | 2010-12-09 | Ihi Corp | アライメントステージ |
| EP2454239B1 (en) | 2009-07-15 | 2014-08-13 | Janssen Pharmaceuticals Inc. | Substituted triazole and imidazole derivatives as gamma secretase modulators |
-
2009
- 2009-12-15 PA PA20098854101A patent/PA8854101A1/es unknown
- 2009-12-16 AP AP2011005692A patent/AP2011005692A0/xx unknown
- 2009-12-16 ES ES09797025.5T patent/ES2460642T3/es active Active
- 2009-12-16 UA UAA201105485A patent/UA104151C2/ru unknown
- 2009-12-16 EP EP09797025.5A patent/EP2379552B1/en active Active
- 2009-12-16 AU AU2009327103A patent/AU2009327103B2/en not_active Ceased
- 2009-12-16 BR BRPI0922664A patent/BRPI0922664A2/pt not_active IP Right Cessation
- 2009-12-16 SG SG2011044310A patent/SG172213A1/en unknown
- 2009-12-16 MX MX2011006543A patent/MX2011006543A/es active IP Right Grant
- 2009-12-16 CA CA2742914A patent/CA2742914A1/en not_active Abandoned
- 2009-12-16 US US13/133,027 patent/US8546440B2/en active Active
- 2009-12-16 WO PCT/EP2009/067321 patent/WO2010070008A1/en active Application Filing
- 2009-12-16 EA EA201170829A patent/EA018625B1/ru not_active IP Right Cessation
- 2009-12-16 NZ NZ594036A patent/NZ594036A/xx not_active IP Right Cessation
- 2009-12-16 JP JP2011541412A patent/JP2012512831A/ja active Pending
- 2009-12-16 KR KR1020117016065A patent/KR20110102455A/ko not_active Application Discontinuation
- 2009-12-16 CN CN200980151827.XA patent/CN102256974B/zh active Active
- 2009-12-17 AR ARP090104939A patent/AR074771A1/es not_active Application Discontinuation
- 2009-12-17 TW TW098143263A patent/TWI438203B/zh not_active IP Right Cessation
-
2011
- 2011-06-15 IL IL213563A patent/IL213563A/en not_active IP Right Cessation
- 2011-06-17 ZA ZA2011/04504A patent/ZA201104504B/en unknown
-
2015
- 2015-06-25 JP JP2015127609A patent/JP2015164969A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015164969A (ja) | 2015-09-17 |
| KR20110102455A (ko) | 2011-09-16 |
| US20110237580A1 (en) | 2011-09-29 |
| UA104151C2 (ru) | 2014-01-10 |
| BRPI0922664A2 (pt) | 2016-01-05 |
| TW201035093A (en) | 2010-10-01 |
| JP2012512831A (ja) | 2012-06-07 |
| SG172213A1 (en) | 2011-07-28 |
| US8546440B2 (en) | 2013-10-01 |
| IL213563A0 (en) | 2011-07-31 |
| NZ594036A (en) | 2012-10-26 |
| CA2742914A1 (en) | 2010-06-24 |
| PA8854101A1 (es) | 2010-07-27 |
| AU2009327103B2 (en) | 2014-12-04 |
| EA018625B1 (ru) | 2013-09-30 |
| TWI438203B (zh) | 2014-05-21 |
| EP2379552B1 (en) | 2014-02-26 |
| WO2010070008A1 (en) | 2010-06-24 |
| MX2011006543A (es) | 2011-07-20 |
| EP2379552A1 (en) | 2011-10-26 |
| AP2011005692A0 (en) | 2011-06-30 |
| CN102256974A (zh) | 2011-11-23 |
| CN102256974B (zh) | 2014-07-30 |
| ES2460642T3 (es) | 2014-05-14 |
| EA201170829A1 (ru) | 2011-12-30 |
| IL213563A (en) | 2015-06-30 |
| ZA201104504B (en) | 2014-01-29 |
| AU2009327103A1 (en) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074771A1 (es) | Derivados de imidazol biciclicos sustituidos como moduladores de gamma secretasa | |
| AR075520A1 (es) | Nuevos derivados sustituidos de benzoxazol bencimidazol oxazolopiridina e imidazopiridina como moduladores de gamma secretasa | |
| MX2014000626A (es) | Nuevos derivados de indol sustituidos como moduladores de gamma secretasa. | |
| AR059339A1 (es) | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene | |
| EA201171363A1 (ru) | Новые замещенные производные индазола и азаиндазола в качестве модуляторов гамма-секретазы | |
| CO6630154A2 (es) | Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos | |
| AR075366A1 (es) | Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa | |
| AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR074359A1 (es) | Compuestos heterociclicos sustituidos como moduladores de canales ionicos | |
| NZ588994A (en) | Phenyl and benzodioxinyl substituted indazoles derivatives | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| PH12016502037A1 (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
| ECSP088965A (es) | Derivados de 2-tioxantina que actúan como inhibidores de la mpo | |
| CR11683A (es) | Piridinas y pirazinas como inhibidores de p13k | |
| EA201290654A1 (ru) | Новые замещенные триазольные производные как модуляторы гамма-секретазы | |
| UY30334A1 (es) | Derivados de triazolopirazina | |
| AR078121A1 (es) | Compuestos de sales de amonio cuaternario y composiciones farmaceuticas | |
| AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
| MX2013011551A (es) | Compuestos y derivados hetero - biciclicos n - sustituidos para combatir las pestes en animales. | |
| ECSP11011427A (es) | Piperidinas sustituidas como antagonistas de ccr3. | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| MX2011010415A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
| MY161094A (en) | Anti-tumor effect potentiator | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| MX2011010311A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |